The  ||| S:0 E:4 ||| DT
roles  ||| S:4 E:10 ||| NNS
of  ||| S:10 E:13 ||| IN
parathyroid  ||| S:13 E:25 ||| JJ
hormone  ||| S:25 E:33 ||| NN
in  ||| S:33 E:36 ||| IN
bone  ||| S:36 E:41 ||| NN
remodeling ||| S:41 E:51 ||| NN
:  ||| S:51 E:53 ||| :
prospects  ||| S:53 E:63 ||| NNS
for  ||| S:63 E:67 ||| IN
novel  ||| S:67 E:73 ||| NN
therapeutics  ||| S:73 E:86 ||| VBD
The  ||| S:86 E:90 ||| DT
aim  ||| S:90 E:94 ||| NN
of  ||| S:94 E:97 ||| IN
this  ||| S:97 E:102 ||| DT
review  ||| S:102 E:109 ||| NN
is  ||| S:109 E:112 ||| VBZ
to  ||| S:112 E:115 ||| TO
focus  ||| S:115 E:121 ||| VB
on  ||| S:121 E:124 ||| IN
the  ||| S:124 E:128 ||| DT
roles  ||| S:128 E:134 ||| NNS
of  ||| S:134 E:137 ||| IN
PTH  ||| S:137 E:141 ||| NNP
in  ||| S:141 E:144 ||| IN
bone  ||| S:144 E:149 ||| NN
remodeling ||| S:149 E:159 ||| NN
.  ||| S:159 E:161 ||| .
PTH  ||| S:161 E:165 ||| NNP
plays  ||| S:165 E:171 ||| VBZ
a  ||| S:171 E:173 ||| DT
central  ||| S:173 E:181 ||| JJ
role  ||| S:181 E:186 ||| NN
in  ||| S:186 E:189 ||| IN
regulating  ||| S:189 E:200 ||| VBG
calcium-phosphate  ||| S:200 E:218 ||| JJ
metabolism  ||| S:218 E:229 ||| NN
and  ||| S:229 E:233 ||| CC
its  ||| S:233 E:237 ||| PRP$
production  ||| S:237 E:248 ||| NN
increases  ||| S:248 E:258 ||| NNS
in  ||| S:258 E:261 ||| IN
response  ||| S:261 E:270 ||| NN
to  ||| S:270 E:273 ||| TO
low  ||| S:273 E:277 ||| JJ
serum  ||| S:277 E:283 ||| JJ
calcium  ||| S:283 E:291 ||| NN
levels ||| S:291 E:297 ||| NNS
.  ||| S:297 E:299 ||| .
A  ||| S:299 E:301 ||| DT
continue  ||| S:301 E:310 ||| VBP
hypersecretion  ||| S:310 E:325 ||| VBN
of  ||| S:325 E:328 ||| IN
PTH ||| S:328 E:331 ||| NNP
,  ||| S:331 E:333 ||| ,
as  ||| S:333 E:336 ||| RB
occurs  ||| S:336 E:343 ||| VBZ
in  ||| S:343 E:346 ||| IN
primary  ||| S:346 E:354 ||| JJ
hyperparathyroidism ||| S:354 E:373 ||| NN
,  ||| S:373 E:375 ||| ,
leads  ||| S:375 E:381 ||| VBZ
to  ||| S:381 E:384 ||| TO
bone  ||| S:384 E:389 ||| VB
resorption ||| S:389 E:399 ||| NNS
.  ||| S:399 E:401 ||| .
On  ||| S:401 E:404 ||| IN
the  ||| S:404 E:408 ||| DT
other  ||| S:408 E:414 ||| JJ
hand ||| S:414 E:418 ||| NN
,  ||| S:418 E:420 ||| ,
there  ||| S:420 E:426 ||| EX
is  ||| S:426 E:429 ||| VBZ
clear  ||| S:429 E:435 ||| JJ
evidence  ||| S:435 E:444 ||| NN
of  ||| S:444 E:447 ||| IN
the  ||| S:447 E:451 ||| DT
anabolic  ||| S:451 E:460 ||| JJ
properties  ||| S:460 E:471 ||| NNS
of  ||| S:471 E:474 ||| IN
PTH.When  ||| S:474 E:483 ||| CD
administered  ||| S:483 E:496 ||| NN
at  ||| S:496 E:499 ||| IN
a  ||| S:499 E:501 ||| DT
low  ||| S:501 E:505 ||| JJ
dose  ||| S:505 E:510 ||| NN
and  ||| S:510 E:514 ||| CC
intermittently ||| S:514 E:528 ||| NN
,  ||| S:528 E:530 ||| ,
this  ||| S:530 E:535 ||| DT
hormone  ||| S:535 E:543 ||| NN
seems  ||| S:543 E:549 ||| VBZ
to  ||| S:549 E:552 ||| TO
be  ||| S:552 E:555 ||| VB
able  ||| S:555 E:560 ||| JJ
to  ||| S:560 E:563 ||| TO
exert  ||| S:563 E:569 ||| VB
positive  ||| S:569 E:578 ||| JJ
effects  ||| S:578 E:586 ||| NNS
on  ||| S:586 E:589 ||| IN
bone  ||| S:589 E:594 ||| NN
volume  ||| S:594 E:601 ||| NN
and  ||| S:601 E:605 ||| CC
microarchitecture ||| S:605 E:622 ||| NN
.  ||| S:622 E:624 ||| .
The  ||| S:624 E:628 ||| DT
effects  ||| S:628 E:636 ||| NNS
of  ||| S:636 E:639 ||| IN
PTH  ||| S:639 E:643 ||| NNP
are  ||| S:643 E:647 ||| VBP
mediated  ||| S:647 E:656 ||| VBN
by  ||| S:656 E:659 ||| IN
PTH ||| S:659 E:662 ||| NNP
/ ||| S:662 E:663 ||| NNP
PTH-related  ||| S:663 E:675 ||| JJ
protein  ||| S:675 E:683 ||| NN
receptor ||| S:683 E:691 ||| NN
,  ||| S:691 E:693 ||| ,
a  ||| S:693 E:695 ||| DT
G  ||| S:695 E:697 ||| NNP
protein  ||| S:697 E:705 ||| NN
that  ||| S:705 E:710 ||| WDT
can  ||| S:710 E:714 ||| MD
activate  ||| S:714 E:723 ||| VB
the  ||| S:723 E:727 ||| DT
cAMP-dependent  ||| S:727 E:742 ||| JJ
protein  ||| S:742 E:750 ||| NN
kinase  ||| S:750 E:757 ||| NNS
( ||| S:757 E:758 ||| -LRB-
PK ||| S:758 E:760 ||| NNP
) ||| S:760 E:761 ||| -RRB-
A  ||| S:761 E:763 ||| NNP
and  ||| S:763 E:767 ||| CC
calcium-dependent  ||| S:767 E:785 ||| NNP
PKC ||| S:785 E:788 ||| NNP
;  ||| S:788 E:790 ||| :
the  ||| S:790 E:794 ||| DT
activation  ||| S:794 E:805 ||| NN
of  ||| S:805 E:808 ||| IN
PKA  ||| S:808 E:812 ||| NNP
account  ||| S:812 E:820 ||| NN
for  ||| S:820 E:824 ||| IN
most  ||| S:824 E:829 ||| JJS
of  ||| S:829 E:832 ||| IN
the  ||| S:832 E:836 ||| DT
PTH  ||| S:836 E:840 ||| NNP
anabolic  ||| S:840 E:849 ||| JJ
action ||| S:849 E:855 ||| NN
.  ||| S:855 E:857 ||| .
The  ||| S:857 E:861 ||| DT
anabolic  ||| S:861 E:870 ||| JJ
actions  ||| S:870 E:878 ||| NNS
of  ||| S:878 E:881 ||| IN
PTH  ||| S:881 E:885 ||| NNP
involve  ||| S:885 E:893 ||| VBP
direct  ||| S:893 E:900 ||| JJ
effects  ||| S:900 E:908 ||| NNS
on  ||| S:908 E:911 ||| IN
osteoblasts  ||| S:911 E:923 ||| NN
and  ||| S:923 E:927 ||| CC
indirect  ||| S:927 E:936 ||| JJ
effects  ||| S:936 E:944 ||| NNS
mediated  ||| S:944 E:953 ||| VBN
by  ||| S:953 E:956 ||| IN
activation  ||| S:956 E:967 ||| NN
of  ||| S:967 E:970 ||| IN
skeletal  ||| S:970 E:979 ||| JJ
growth  ||| S:979 E:986 ||| NN
factors  ||| S:986 E:994 ||| NNS
( ||| S:994 E:995 ||| -LRB-
IGF-I ||| S:995 E:1000 ||| NNP
)  ||| S:1000 E:1002 ||| -RRB-
and  ||| S:1002 E:1006 ||| CC
inhibition  ||| S:1006 E:1017 ||| NN
of  ||| S:1017 E:1020 ||| IN
growth  ||| S:1020 E:1027 ||| NN
factor  ||| S:1027 E:1034 ||| NN
antagonists ||| S:1034 E:1045 ||| NNS
,  ||| S:1045 E:1047 ||| ,
such  ||| S:1047 E:1052 ||| JJ
as  ||| S:1052 E:1055 ||| IN
sclerostin ||| S:1055 E:1065 ||| NN
.  ||| S:1065 E:1067 ||| .
PTH  ||| S:1067 E:1071 ||| NNP
enhances  ||| S:1071 E:1080 ||| VBZ
the  ||| S:1080 E:1084 ||| DT
number  ||| S:1084 E:1091 ||| NN
and  ||| S:1091 E:1095 ||| CC
the  ||| S:1095 E:1099 ||| DT
activation  ||| S:1099 E:1110 ||| NN
of  ||| S:1110 E:1113 ||| IN
osteoblast  ||| S:1113 E:1124 ||| NN
through  ||| S:1124 E:1132 ||| IN
4  ||| S:1132 E:1134 ||| CD
pathways ||| S:1134 E:1142 ||| NNS
:  ||| S:1142 E:1144 ||| :
increasing  ||| S:1144 E:1155 ||| VBG
osteoblast  ||| S:1155 E:1166 ||| JJ
proliferation  ||| S:1166 E:1180 ||| NN
and  ||| S:1180 E:1184 ||| CC
differentiation ||| S:1184 E:1199 ||| NN
,  ||| S:1199 E:1201 ||| ,
decreasing  ||| S:1201 E:1212 ||| VBG
osteoblast  ||| S:1212 E:1223 ||| JJ
apoptosis  ||| S:1223 E:1233 ||| NN
and  ||| S:1233 E:1237 ||| CC
reducing  ||| S:1237 E:1246 ||| VBG
the  ||| S:1246 E:1250 ||| DT
negative  ||| S:1250 E:1259 ||| JJ
effects  ||| S:1259 E:1267 ||| NNS
of  ||| S:1267 E:1270 ||| IN
peroxisome  ||| S:1270 E:1281 ||| FW
proliferator  ||| S:1281 E:1294 ||| FW
activator  ||| S:1294 E:1304 ||| FW
( ||| S:1304 E:1305 ||| -LRB-
PPAR ||| S:1305 E:1309 ||| NNP
) ||| S:1309 E:1310 ||| -RRB-
γ  ||| S:1310 E:1312 ||| JJ
receptor  ||| S:1312 E:1321 ||| NN
on  ||| S:1321 E:1324 ||| IN
osteoblast  ||| S:1324 E:1335 ||| JJ
differentiation ||| S:1335 E:1350 ||| NN
.  ||| S:1350 E:1352 ||| .
Moreover  ||| S:1352 E:1361 ||| RB
PTH  ||| S:1361 E:1365 ||| NNP
enhances  ||| S:1365 E:1374 ||| VBZ
the  ||| S:1374 E:1378 ||| DT
Wnt-β  ||| S:1378 E:1384 ||| JJ
catenin  ||| S:1384 E:1392 ||| JJ
pathway ||| S:1392 E:1399 ||| NN
,  ||| S:1399 E:1401 ||| ,
that  ||| S:1401 E:1406 ||| WDT
is  ||| S:1406 E:1409 ||| VBZ
central  ||| S:1409 E:1417 ||| JJ
to  ||| S:1417 E:1420 ||| TO
osteogenesis  ||| S:1420 E:1433 ||| VB
and  ||| S:1433 E:1437 ||| CC
bone  ||| S:1437 E:1442 ||| NN
formation ||| S:1442 E:1451 ||| NN
,  ||| S:1451 E:1453 ||| ,
inhibiting  ||| S:1453 E:1464 ||| JJ
sclerostin ||| S:1464 E:1474 ||| NN
.  ||| S:1474 E:1476 ||| .
Finally ||| S:1476 E:1483 ||| RB
,  ||| S:1483 E:1485 ||| ,
PTH  ||| S:1485 E:1489 ||| NNP
induces  ||| S:1489 E:1497 ||| VBZ
the  ||| S:1497 E:1501 ||| DT
synthesis  ||| S:1501 E:1511 ||| NN
of  ||| S:1511 E:1514 ||| IN
IGF-I  ||| S:1514 E:1520 ||| JJ
and ||| S:1520 E:1523 ||| CC
,  ||| S:1523 E:1525 ||| ,
due  ||| S:1525 E:1529 ||| JJ
to  ||| S:1529 E:1532 ||| TO
its  ||| S:1532 E:1536 ||| PRP$
prodifferentiating  ||| S:1536 E:1555 ||| NN
and  ||| S:1555 E:1559 ||| CC
pro-survival  ||| S:1559 E:1572 ||| JJ
effects  ||| S:1572 E:1580 ||| NNS
on  ||| S:1580 E:1583 ||| IN
osteoblasts ||| S:1583 E:1594 ||| NN
,  ||| S:1594 E:1596 ||| ,
this  ||| S:1596 E:1601 ||| DT
could  ||| S:1601 E:1607 ||| MD
be  ||| S:1607 E:1610 ||| VB
a  ||| S:1610 E:1612 ||| DT
key  ||| S:1612 E:1616 ||| JJ
mediator  ||| S:1616 E:1625 ||| NN
of  ||| S:1625 E:1628 ||| IN
PTH  ||| S:1628 E:1632 ||| NNP
effect  ||| S:1632 E:1639 ||| NN
on  ||| S:1639 E:1642 ||| IN
osteoblasts ||| S:1642 E:1653 ||| NN
.  ||| S:1653 E:1655 ||| .
In  ||| S:1655 E:1658 ||| IN
conclusion ||| S:1658 E:1668 ||| NN
,  ||| S:1668 E:1670 ||| ,
the  ||| S:1670 E:1674 ||| DT
intermittent  ||| S:1674 E:1687 ||| JJ
administration  ||| S:1687 E:1702 ||| NN
of  ||| S:1702 E:1705 ||| IN
PTH  ||| S:1705 E:1709 ||| NNP
has  ||| S:1709 E:1713 ||| VBZ
a  ||| S:1713 E:1715 ||| DT
pleiotropic  ||| S:1715 E:1727 ||| JJ
anabolic  ||| S:1727 E:1736 ||| JJ
effect  ||| S:1736 E:1743 ||| NN
on  ||| S:1743 E:1746 ||| IN
bone ||| S:1746 E:1750 ||| NN
;  ||| S:1750 E:1752 ||| :
further  ||| S:1752 E:1760 ||| JJ
studies  ||| S:1760 E:1768 ||| NNS
about  ||| S:1768 E:1774 ||| IN
mechanisms  ||| S:1774 E:1785 ||| NNS
of  ||| S:1785 E:1788 ||| IN
action  ||| S:1788 E:1795 ||| NN
of  ||| S:1795 E:1798 ||| IN
PTH  ||| S:1798 E:1802 ||| NNP
could  ||| S:1802 E:1808 ||| MD
be  ||| S:1808 E:1811 ||| VB
a  ||| S:1811 E:1813 ||| DT
starting  ||| S:1813 E:1822 ||| VBG
point  ||| S:1822 E:1828 ||| NN
to  ||| S:1828 E:1831 ||| TO
new  ||| S:1831 E:1835 ||| JJ
osteoporosis  ||| S:1835 E:1848 ||| JJ
treatments ||| S:1848 E:1858 ||| NNS
.  ||| S:1858 E:1860 ||| .
